Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
People claim the viral "natural Mounjaro" drink — honey, lemon, water, and ginger — makes you lose weight. Here's what an ...
Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...
24/7 Wall St. on MSN16h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Tesla chief Elon Musk dubbed himself “Ozempic Santa” in an X post on Christmas Day, marking the tech billionaire’s latest ...
Mounjaro (tirzepatide) has potential interactions with other medications and some supplements. For example, Mounjaro can interact with Adderall and oral birth control. An interaction can occur ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback